Global Ischemic Heart Disease (IHD) Drugs Market to grow with a CAGR of 4.20%
Increasing healthcare infrastructure and
a supportive regulatory environment are the major drivers for the Global Ischemic
Heart Disease (IHD) Drugs Market.
According to TechSci Research report, “Global
Ischemic Heart Disease (IHD) Drugs Market Industry Size, Share, Trends, Competition, Opportunity and Forecast, 2018-2028”, Global Ischemic Heart Disease (IHD)
Drugs Market has valued at USD 5.98 billion in 2022 and is anticipated to
witness an impressive growth in the forecast period with a CAGR of 4.20%
through 2028. This can be due to collaborations and partnerships among leading
companies with a diverse approach to merge the expertise of individual
companies and to strengthen their position in the market. Awareness and
education play a significant role in driving the demand for ischemic heart
disease (IHD) drugs in the Global IHD Drugs Market. Public awareness campaigns
and educational initiatives help individuals recognize risk factors for IHD,
such as high blood pressure, high cholesterol, smoking, obesity, and sedentary
lifestyles. Increased awareness leads to earlier identification of these risk
factors, prompting individuals to seek medical advice and potentially receive
IHD drug prescriptions. Educating the public about the symptoms of IHD,
including chest pain (angina) and associated warning signs, ensures that
individuals seek medical attention promptly. This can lead to earlier diagnosis
and intervention, potentially involving the use of IHD drugs. Awareness and
education encourage individuals to adopt preventive measures such as a
heart-healthy diet, regular exercise, and smoking cessation. These lifestyle
modifications can reduce the risk of IHD, ultimately decreasing the need for
IHD drugs. Informed patients are more likely to engage in meaningful
discussions with healthcare providers about their risk factors, symptoms, and
treatment options. This open dialogue can result in the appropriate
prescription of IHD drugs when necessary. Patient education about the
importance of adhering to prescribed IHD medication regimens is crucial for
treatment success. When patients understand the role of medications in managing
IHD, they are more likely to take their drugs as directed.
Browse over XX market data Figures and spread through XX Pages and an in-depth TOC on " Global Ischemic Heart Disease (IHD) Drugs Market.”
Ischemic heart disease (IHD) is a heart
condition that typically manifests during periods of excitement and exertion,
when the heart's demand for increased blood supply becomes evident. The
condition is a consequence of arteries supplying the heart being obstructed, a
result of the accumulation of plaque in these arteries. The insufficient blood
supply can lead to recurrent chest pain and discomfort, a condition known as
angina pectoris. In August 2021, Jardiance (empagliflozin) 10 mg has received approval
from the U.S. Food and Drug Administration for reducing the risk of
cardiovascular death and hospitalization due to heart failure in adults
diagnosed with heart failure with reduced ejection fraction (HFrEF), as jointly
announced by Boehringer Ingelheim and Eli Lilly and Company. It is essential to
note that Jardiance is not intended for individuals with type 1 diabetes due to
a potential increased risk of diabetic ketoacidosis. Moreover, its use is not
recommended for the purpose of enhancing glycemic control in adults with type 2
diabetes who have an estimated glomerular filtration rate (eGFR) of less than
30 mL/min/1.73 m2, as its mechanism of action suggests it is likely to be
ineffective in such cases. This regulatory approval for Jardiance is based on
the findings from the EMPEROR-Reduced phase III trial. This trial assessed the
impact of adding Jardiance 10 mg compared to a placebo to the standard
treatment regimen in a diverse group of 3,730 adults, both with and without
type 2 diabetes, who were diagnosed with heart failure (functional class II,
III, or IV) and had a left ventricular ejection fraction of 40% or less.
Adherence
to medication is a significant challenge in the Global Ischemic Heart Disease
(IHD) Drugs Market, as it is in the management of many chronic medical
conditions. IHD, particularly in its early stages, can be asymptomatic, meaning
that patients may not experience obvious symptoms like chest pain (angina).
This lack of immediate symptoms can lead to a false sense of well-being and
reduce the motivation to adhere to medication. Patients with IHD often require
multiple medications, such as antiplatelets, statins, beta-blockers, and
antihypertensives, to manage the condition and its risk factors. The complexity
of managing several medications can be challenging and may lead to
non-adherence. IHD is a chronic condition that often requires long-term or even
lifelong medication. Patients may find it difficult to remain adherent over
extended periods, leading to lapses in treatment. Some IHD medications can have
side effects, such as muscle pain, fatigue, or gastrointestinal issues. These
side effects may discourage patients from taking their medications as
prescribed. The cost of IHD medications, especially when they are not covered
by insurance, can be a barrier to adherence. Patients may skip doses or reduce
their medication intake to save on costs. Medication regimens for IHD can be
complex, requiring multiple daily doses, specific timing, or dietary
restrictions. Patients may struggle to follow these instructions. Forgetting to
take medications, especially for patients with busy lives or cognitive impairments,
can lead to non-adherence.
Global Ischemic Heart
Disease (IHD) Drugs Market is segmented based on Disease, Drug Class, and by
region. Based
on the Disease, Global Ischemic Heart Disease (IHD) Drugs Market is segmented
into Angina
Pectoris, Myocardial Infarction. Angina
pectoris, commonly referred to as angina, is a medical condition characterized
by chest pain or discomfort that occurs when the heart muscle doesn't receive
enough oxygen-rich blood. This condition is typically a symptom of an
underlying heart problem, most commonly ischemic heart disease (IHD) or
coronary artery disease (CAD). Angina occurs when there is a reduced blood
supply to the heart muscle, often due to the narrowing or blockage of the
coronary arteries, which supply blood to the heart. This reduction in blood
flow is primarily caused by atherosclerosis, the buildup of fatty deposits and
cholesterol on the inner walls of the coronary arteries. Angina typically presents
as chest pain or discomfort, which may be described as a feeling of pressure,
squeezing, burning, or heaviness. The pain can also radiate to the arms,
shoulders, neck, jaw, or back. Some individuals may experience shortness of
breath, nausea, or lightheadedness along with chest discomfort. Based on Region, North America held the largest share
in the Global Ischemic Heart Disease (IHD) Drugs Market. North
America has a high healthcare expenditure per capita, which allows patients to
access advanced treatments and medications, including expensive IHD drugs. The
region actively promotes heart health awareness and conducts screening and
prevention programs. This encourages early diagnosis and treatment of IHD,
driving the demand for IHD drugs. Pharmaceutical companies often target the
North American market for drug launches and marketing efforts. This leads to
greater awareness and adoption of IHD drugs in the region. Many clinical trials
for IHD drugs are conducted in North America, involving a substantial patient
population. This not only accelerates the drug development process but also
makes new treatments available to patients in the region sooner.
Some of the major companies operating in
the Global
Ischemic Heart Disease (IHD) Drugs Market include:
- Bayer AG
- Eli Lilly and Company
- Novartis International AG
- Pfizer, Inc.
- Sanofi S.A.
- Actelion Pharmaceuticals Ltd.
- Baxter International Inc.
- Boehringer Ingelheim International GmbH
- Bristol-Myers Squibb Company
- Amgen Inc.
- F. Hoffmann-La Roche AG
Download Free Sample Report
Customers
can also request for 10% free customization on this report.
“Certain
areas, particularly in North America, are projected to exert significant demand
for ischemic heart disease (IHD) Drugs. The growth in the competitive landscape
and the presence of well-established companies in the market, committed to
enhance the overall wellbeing of people each year, are expected to contribute
to a remarkable growth of the Global Ischemic Heart Disease (IHD) Drugs Market
in the forecast period," said Mr. Karan Chechi, Research Director with
TechSci Research, a research-based Global management consulting firm.
Ischemic Heart Disease (IHD) Drugs Market by Disease Class (Angina
Pectoris, Myocardial Infarction), By Drug Class (Anti-Dyslipidemic Drugs, Calcium Channel Blockers,
Beta-Blockers, ACE Inhibitors, ARBs, Vasodilators, Antithrombotic Agents), By Region, By Competition Forecast & Opportunities, 2018-2028F has evaluated the future growth potential of Global
Ischemic Heart Disease (IHD) Drugs Market and provides statistics &
information on market size, structure, and future market growth. The report
intends to provide innovative market intelligence and help decision makers take
sound investment decisions. Besides, the report also identifies and analyzes
the emerging trends along with essential drivers, challenges, and opportunities
in Global Ischemic Heart Disease (IHD) Drugs Market.
Contact
Techsci Research LLC
420 Lexington Avenue, Suite 300,
New York, United States- 10170
Tel: +13322586602
Email: [email protected]
Website: www.techsciresearch.com